A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma

Trial Profile

A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 May 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab
  • Indications Follicular lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Oct 2016 Results published in the Blood.
    • 08 Dec 2015 Results (n=22) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Dec 2015 Results will be presented at the 57th Annual American Society of Hematology (ASH) Meeting and Exposition, as per AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top